This study is looking at people with Chronic Granulomatous Disease (CGD) to understand more about their immune system. Researchers want to measure the levels of certain antibodies (proteins that fight infections) and cytokines (proteins that help control inflammation) in your blood. This will help them learn about how common these markers are in people with CGD. You could join if you have CGD, which means your doctor has confirmed that your white blood cells don't work properly (NADPH oxidase activity is ≤5% or you have a specific gene change). The study aims to find out the levels of total adenoviral-specific antibody (TAb) and adenoviral-specific neutralizing antibody (NAb) in your blood. This is an observational study, meaning researchers will collect information without giving you any new treatments. The study is currently unclear about its recruitment status and plans to include 60 participants.

Study design

This is an observational study that plans to include 60 participants. It is not a randomized or blinded study.

What's involved

Blood samples will be collected from you. The levels of certain antibodies and inflammatory cytokines will be measured from these samples.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints (antibody levels) are measured at 1 Day. It is not specified if there is follow-up beyond this.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.